Degussa sells Proligo nucleic acid Group to Sigma-Aldrich
Annual sales at Proligo, which employs around 300 staff worldwide, totaled 30.9 million euros in 2004. Proligo operates in the field of nucleic acids and oligonucleotide synthesis, with sites in Hamburg, Paris, Boulder, Singapore, Kyoto and Lismore/Australia.
Ranking sixth in the oligonucleotides market Proligo does not have the opportunities to achieve a leading position through its own resources. Moreover, this market is expected to face heavy consolidation. As a result, Degussa has been evaluating strategic options for Proligo over the past few months.
Most read news
Organizations
Other news from the department business & finance
Get the life science industry in your inbox
From now on, don't miss a thing: Our newsletter for biotechnology, pharma and life sciences brings you up to date every Tuesday and Thursday. The latest industry news, product highlights and innovations - compact and easy to understand in your inbox. Researched by us so you don't have to.